Cannabis — What the Evidence Actually Shows
Risk concentrated in specific patterns of use, not evenly spread
Cannabis is a genuinely mixed-evidence substance — real documented risks, but concentrated in specific use patterns rather than applying evenly to any and all use, which is worth being precise about rather than either dismissing or overstating the risk.
The Psychosis Risk Evidence
A large multi-site European case-control study comparing 901 patients experiencing a first episode of psychosis against 1,237 matched controls found daily cannabis users had over three times the odds of psychosis compared to non-users, rising to nearly five times the odds for daily users of high-potency cannabis specifically (defined as THC concentration above 10%)[4]. Critically, 29.5% of first-episode psychosis patients reported daily cannabis use, compared to just 6.8% of controls — a striking gap. The risk in this study was concentrated specifically in daily use and high-potency products; the data does not show anything like this risk elevation for infrequent or lower-potency use.
Early warning signs worth noticing, in yourself or someone close to you, include new or worsening paranoia, disorganised or hard-to-follow thinking, and unusual suspiciousness of other people's motives. None of these confirms psychosis on its own, but they're worth a conversation with a doctor, particularly alongside daily high-potency use.
Other Documented Effects
THC disrupts the endocannabinoid system — a network of receptors throughout the brain and body involved in regulating mood, appetite, and (relevant here) brain development, among other things. That network is still actively developing through adolescence, which is why use during this period carries disproportionate risk to brain development compared to adult use. In adults, regular heavy use is separately linked to working memory impairment and reduced motivation, independent of the psychosis-risk findings above.
CBD without THC has a substantially better safety profile and has been studied for anxiety, pain, and inflammation without the intoxicating or psychosis-risk properties associated with THC.
Cannabis is not physically addictive in the way opioids are, but psychological dependence and tolerance are well documented, particularly with daily use.
Section takeaway
The strongest cannabis risk evidence is specific, not general: daily use and high-potency products carry a documented, substantial psychosis-risk elevation, and adolescent use carries disproportionate developmental risk. Occasional, lower-potency adult use sits on a meaningfully different risk profile.